Real-life effectiveness of indacaterol–glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study

References

• TashkinDPFergusonGTCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseRespir Res2013144923651244
   PubMed Web of Science ®Google Scholar
• Dang-TanTIsmailaAZhangSZarotskyVBernauerMClinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic reviewBMC Res Notes20158146426391471
   PubMedGoogle Scholar
• Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease2017
   Google Scholar
• O’DonnellDEAaronSBourbeauJCanadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 updateCan Respir J200714Suppl B5B32B
   PubMed Web of Science ®Google Scholar
• BourbeauJBhutaniMHernandezPCTS position statement: pharmacotherapy in patients with COPD – an updateCanadian Journal of Respiratory, Critical Care, and Sleep Medicine201714222241
   Web of Science ®Google Scholar
• AgustiAFabbriLMSinghDInhaled corticosteroids in COPD: Friend or foe?Eur Respir J Epub201896
   Web of Science ®Google Scholar
• VestboJVogelmeierCSmallMHigginsVUnderstanding the GOLD 2011 Strategy as applied to a real-world COPD populationRespir Med2014108572973624675239
   PubMed Web of Science ®Google Scholar
• BourbeauJSebaldtRJDayAPractice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE studyCan Respir J2008151131918292848
   PubMed Web of Science ®Google Scholar
• PriceDWestDBrusselleGManagement of COPD in the UK primary-care setting: an analysis of real-life prescribing patternsInt J Chron Obstruct Pulmon Dis2014988990525210450
   PubMed Web of Science ®Google Scholar
• HernandezPBalterMSBourbeauJChanCKMarciniukDDWalkerSLCanadian practice assessment in chronic obstructive pulmonary disease: respiratory specialist physician perception versus patient realityCan Respir J20132029710523616966
   PubMed Web of Science ®Google Scholar
• RossiAvan der MolenTdel OlmoRINSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPDEur Respir J20144461548155625359348
   PubMed Web of Science ®Google Scholar
• PriceDYawnBBrusselleGRossiARisk-to-benefit ratio of inhaled corticosteroids in patients with COPDPrim Care Respir J20132219210023135217
   PubMedGoogle Scholar
• RossiAGuerrieroMCorradoAOPTIMO/AIPO Study GroupWithdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO)Respir Res20141517725005873
   PubMed Web of Science ®Google Scholar
• MagnussenHDisseBRodriguez-RoisinRWithdrawal of inhaled glucocorticoids and exacerbations of COPDN Engl J Med2014371141285129425196117
   PubMed Web of Science ®Google Scholar
• VogelmeierCFBatemanEDPallanteJEfficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyLancet Respir Med201311516024321804
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• MahlerDADecramerMD’UrzoADual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE studyEur Respir J20144361599160924176997
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• FordINorrieJTrialsPPragmatic TrialsN Engl J Med2016375545446327518663
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• DransfieldMTBaileyWCraterGEmmettAO’DellDMYawnBDisease severity and symptoms among patients receiving monotherapy for COPDPrim Care Respir J2011201465320886200
   PubMedGoogle Scholar
• ZhongNWangCZhouXLANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPDInt J Chron Obstruct Pulmon Dis2015101015102626082625
   PubMed Web of Science ®Google Scholar
• VogelmeierCFGagaMAalamian-MattheisMEfficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trialRespir Res201718114028720132
   PubMed Web of Science ®Google Scholar
• JonesPWBrusselleGdal NegroRWProperties of the COPD assessment test in a cross-sectional European studyEur Respir J2011381293521565915
   PubMed Web of Science ®Google Scholar
• SmidDEFranssenFMHouben-WilkeSResponsiveness and MCID Estimates for CAT, CCQ, and HADS in Patients With COPD Undergoing Pulmonary Rehabilitation: A Prospective AnalysisJ Am Med Dir Assoc2017181535827624705
   PubMed Web of Science ®Google Scholar
• KonSSCanavanJLJonesSEMinimum clinically important difference for the COPD Assessment Test: a prospective analysisLancet Respir Med20142319520324621681
   PubMed Web of Science ®Google Scholar
• BuhlRCriéeCPKardosPDual bronchodilation vs triple therapy in the “real-life” COPD DACCORD studyInt J Chron Obstruct Pulmon Dis2018132557256830197512
   PubMed Web of Science ®Google Scholar
• SuissaSPatenaudeVLapiFErnstPInhaled corticosteroids in COPD and the risk of serious pneumoniaThorax201368111029103624130228
   PubMed Web of Science ®Google Scholar
• VestboJAndersonJABrookRDFluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trialLancet2016387100301817182627203508
   PubMed Web of Science ®Google Scholar
• SuissaSErnstPPrecision Medicine Urgency: The Case of Inhaled Corticosteroids in COPDChest2017152222723128797382
   PubMed Web of Science ®Google Scholar
• PascoeSLocantoreNDransfieldMTBarnesNCPavordIDBlood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trialsLancet Respir Med20153643544225878028
   PubMed Web of Science ®Google Scholar
• RocheNChapmanKRVogelmeierCFBlood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME TrialAm J Respir Crit Care Med201719591189119728278391
   PubMed Web of Science ®Google Scholar
• PapiAKostikasKWedzichaJADual bronchodilation response by exacerbation history and eosinophilia in the FLAME studyAm J Respir Crit Care Med201819771223122629099609
   PubMed Web of Science ®Google Scholar
• WatzHTetzlaffKWoutersEFBlood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trialLancet Respir Med20164539039827066739
   PubMed Web of Science ®Google Scholar
• ChapmanKRHurstJRFrentSMLong-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trialAm J Respir Crit Care Med2018198332933929779416
   PubMed Web of Science ®Google Scholar
• SinghDPapiACorradiMSingle inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trialLancet20163881004896397327598678
   PubMed Web of Science ®Google Scholar
• LipsonDABarnacleHBirkRFULFIL Trial: Once-daily triple therapy for patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2017196443844628375647
   PubMed Web of Science ®Google Scholar
• FergusonGTRabeKFMartinezFJTriple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trialLancet Respir Med201861074775830232048
   PubMed Web of Science ®Google Scholar
• LipsonDABarnhartFBrealeyNOnce-daily single-inhaler triple versus dual therapy in patients with COPDN Engl J Med2018378181671168029668352
   PubMed Web of Science ®Google Scholar
• PapiAVestboJFabbriLExtrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trialLancet2018391101251076108429429593
   PubMed Web of Science ®Google Scholar
• AgustiAFilling the gaps in COPD: the TRIBUTE studyLancet2018391101251004100629429594
   PubMed Web of Science ®Google Scholar
• SuissaSDrazenJMMaking sense of triple inhaled therapy for COPDN Engl J Med2018378181723172429669218
   PubMed Web of Science ®Google Scholar
• CalverleyPMAAnzuetoARCarterKTiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trialLancet Respir Med20186533734429605624
   PubMed Web of Science ®Google Scholar